Articles By Jack Cush, MD
Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).
Read Article
Carpal Tunnel - Steroid injection vs. Night Splinting
A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.
Read Article
Big Time Vasculitis (3.10.2023)
Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?
Read Article
Long-Term Survival of Idiopathic Inflammatory Myopathies
A single center cohort study analyzed the outcome and survival of idiopathic inflammatory myositis (IIM) patients and showed good 5 and 10 year survival but showed significant declined 15-25 years post-diagnosis.
Read Article
Geo-epidemiology of Autoantibodies in Rheumatoid Arthritis
A multinational study of rheumatoid arthritis (RA) patients shows a variety of post-translationally modified anti-modified protein antibodies (AMPA). While AMPA differed in different ethnic populations, their levels correlated with total serum IgG.
Read Article
Higher Rehospitalization Rates in Younger SLE Patients
A Medicare study shows that young adults with systemic lupus erythematosus (SLE) exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients.
Read Article
Does Methotrexate Work in Alopecia Universalis?
Alopecia areata totalis (AT) and universalis (AU) are the most severe and difficult to treat forms of alopecia areata (AA).
Read Article
Does Biologic Treatment in Psoriasis Reduce the Risk of Psoriatic Arthritis?
Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.
Read Article
Long-Term Benefit of Rituximab in Systemic Sclerosis
A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.
Read Article
NSAIDs in Pregnancy (3.3.2023)
Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow. This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.
Read Article
